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Abstract  During  the  last  decades,  LDL-apheresis  was 
established  as  an  extracorporeal  treatment  option  for  pa-
tients  with  severe  heterozygous  or  homozygous  familial 
hypercholesterolemia (FH) that is resistant to conventional 
treatment strategies such as diet, drugs, and changes in life-
style.  Nearly  half  a  century  ago,  the  first  LDL-apheresis 










tion during a single  treatment  is  rather  similar and  ranges 
between  55  and  65  %  of  the  pretreatment  LDL  plasma 
concentration.
In the 1990s, the patients regularly treated by extracor-
poreal LDL-elimination,  diet,  and  drugs were  included  in 









therapeutic  benefit  of  this  expensive  and  time-consuming 
therapeutic approach.
Furthermore,  the  future  of  LDL-apheresis will  depend 
upon  the  availability  of  highly  efficient  new  drugs  and 
molecular  genetic  approaches  such  as  RNA  silencing  of 
the apoB gene, whereas  the liver  transplantation and gene 
therapy  of  the  LDL-receptor  deficiency  will  not  replace 









mon  inherited  metabolic  diseases,  caused  in  most  cases 
by  different  mutations  of  the  LDL  receptor.  Previously, 
this  disease  in  its  homozygous  form  resulted  in  the  early 






































treatment  could  be  successfully  used  for  the  first  time  in 
1960 [38].
For the treatment of FH, the concept of a plasma exchange 



















The  immunoadsorption  of  apolipoprotein  (Apo)  B  is 
based on  its  binding  to  immobilized  anti-apoB antibodies 
[41].  The  immunoapheresis  is  thus  a  very  specific  LDL 
apheresis method, eliminating all ApoB containing lipopro-
tein  particles  such  as LDL, Lp(a),  and  some VLDL  [32]. 
Later,  this  method was modified  by  the  use  of monoclo-
nal antibodies against ApoB or specific antibodies against 
Lp(a), respectively [28].









ved filtering  technologies,  the  actual device  reduces  albu-
min and HDL to a less extent than IgM [51, 10].
In  the mid  1980s,  chemically  defined ApoB-adsorbing 
polyanions  such  as  dextran  sulfate  or  heparin were  cova-
















Year of introduction Procedure Principle LDL-reduction (%) Reference
1966 Plasmapheresis LDL-elimination by plasma exchange [7]
1980 Heparin-adsorption LDL-adsorption (Plasma) [21]
1981 Immunoadsorption LDL-adsorption (Plasma) 35–56 [41]
1983 Differential filtration LDL-filtration (Plasma) 56–62 [51]
1984 Dextran sulfate adsorption LDL-adsorption (Plasma) 49–75 [55]









extracorporeal  LDL  precipitation)  is  one  of  the  standard 
methods of extracorporeal LDL-elimination.
A further  technological step  in  the early 1990s was  the 
development  of  a  whole  blood  LDL-apheresis  device, 
named DALI  (Direct Adsorption  of Lipids), which  remo-
ves  LDL,  VLDL,  and  Lp(a)  directly  from  whole  blood. 
Because  this  system does not need any plasma separation 
step,  the handling of  the procedure is  in some way easier. 















volume  of  plasma,  the  reduction  rates  for ApoB-carrying 












because  of  rapid  lowering  of  triglyceride-rich  lipoprotein 
particles such as VLDL and chylomicrons. However, due to 
their rapid rebound they return very quickly to preapheresis 









clearly above 500 mg/dl  is more sustainable  than  in hete-
rozygous  FH  patients  with  LDL  baseline  values  between 
250–500 mg/dl [37] if one assumes a roughly comparable 
resynthesis rate of LDL.
In  order  to  achieve  optimal  therapeutic  target  value  in 
patients with hypercholesterolemia, the lipid apheresis has 
also been used  in polygenic FH patients with  serum LDL 
levels  below  250 mg/dl  not  responding  to  diet  and  lipid-






Shortly  after  the  introduction of  lipid  apheresis  for  the 
treatment  of  severe  FH,  the  HMG-CoA  reductase  inhibi-







those with  polygenic  hypercholesterolemia,  the  combined 
treatment modality was  so  effective  that  the  interval  bet-
































After  the  introduction  of  selective  LDL-apheresis,  the 
first  achieved  treatment  successes  were  documented  and 
published as case reports. The patients with homozygous or 
severe heterozygous familial hypercholesterolemia resistant 
to  therapy,  and  undergoing  regular  LDL-apheresis,  repor-
ted significant improvement of subjective symptoms, such 











With  a  few  exceptions,  these  so-called  regression  stu-
dies were not conducted in a controlled fashion and had the 
disadvantage of the small number of cases.




One  of  the  two  controlled  and  randomized  regression 









graphy  proved  to  be  progressive whereas  in  the  group  of 








Japanese  colleagues  published  a  historically  control-
led  but  not  randomized  study  (L-CAPS). They  retrospec-
tively  compared  patients  treated  by  regular  apheresis  and 









This means  that  the  initial  coronary  angiography findings 
were documented and compared with the final angiography 
at the end of the study.
The  results of  these  studies have  shown  similar  results 
independent  of  the  lipid  apheresis  system  used: The  pro-
gressive  coronary  stenoses  documented  by  quantitative 
coronary angiography at the start of regular apheresis the-














Study (reference) Apheresis patients (n) Reduction of LDL-cholesterol (%) Quantitative angiography (segment-based analysis; %)
NC R P
HELP [36]   51 62 55 30 15
LARS [43]   37 55 49 38 13
GM [52]   25 58 64 < 1 36
FHRS [49]   20 53 65 25 10
LAARS [19]   20 63 45 10 45











treated  homozygous  twin  sisters  in  the  early  1980s  [48]: 
One sibling underwent plasma exchange treatment at regu-
lar  intervals,  the other was  treated with conventional diet, 
fibrates,  and cholestyramine. Siblings  treated with  regular 











endpoints  of  therapy  such  as  reinfarction  or  death  are  also 



















ring  rates  [9,  47]:  It  is  hardly  conceivable  that  evaluated 
HELP  register  patients  could  have  achieved mean  values 
after  single  treatment  which  correspond  to  target  values 
discussed today.
Currently, in Germany, there are two apheresis registers: 




valid  conclusions  from  these  study  registers,  the merging 











materials,  inter  alia,  complement  is  activated  to  varying 
degrees  [54].  In  the  extracorporeal  system,  the  lipids  and 
proteins can be peroxidized but at  the same time they can 
be eliminated by the apheresis procedure [24]. The impact 
of  eliminating  cytokines  or  chemokines,  in  particular  of 
inflammatory mediators,  is only poorly understood. These 
topics  are,  at  least  if  one  analyzes  the  latest  publications, 





or placed  in context by such pleiotropic effects.  It  is con-
ceivable that the reported subjective and objective clinical 
improvement under apheresis treatment are the expression 




























The decision  to confirm the  indication for  regular LDL 
apheresis in Germany is primarily in the hands of the regio-
nal  apheresis  committees.  They  decide  on  the  basis  of  a 
required  separate opinion of  a  “lipidologist”  and  an  inde-
pendent cardiologist. This setting has only changed little in 




The use  of  apheresis  in  children with  homozygous FH 
is granted for life in general, because for these patients the 
cost-benefit ratio is undoubtedly positive.














However,  in  the  long  term,  both,  costs  and  the  impair-
ment of quality of life by the regular treatments at weekly or 
biweekly intervals have to be considered. The regular appli-
cation of LDL apheresis  also  requires  a permanent venous 
access  similar  to  dialysis  patients  (arteriovenous  fistula), 
which is associated with a certain risk of thrombosis or sepsis.
The combined heart-liver  transplantation or  liver  trans-
plantation  alone  is  therefore  in  fact  a  treatment  alterna-
tive. While  the  regularly  performed  LDL  apheresis  leads 
to a mean reduction of LDL-cholesterol by about 50 %, a 
normalization  of  LDL-cholesterol  is  to  be  expected  after 
successful  transplantation  [22].  On  the  other  hand,  the 









Even  today,  the gene  therapy  is  still no  real alternative  to 
regular lipid apheresis treatment.
The aim of gene therapy in familial hypercholesterolemia 
is  the overexpression of  the LDL  receptor by  insertion of 
the receptor-encoding transgene with the help of a suitable 
vector.  So  far,  the  adenoviruses  or  adeno-associated virus 




at any high  titers  [46]. However,  they have a high  immu-





the  liver  were  performed,  the  hepatocytes  were  isolated, 





An  updated  overview  of  the  now  18-year  tried  appro-
aches to establish a sustainably applicable gene therapy is 
given in a recent review by Al-Allaf [2]. A qualification in 













The  role  of  LDL-apheresis  will  lose  its  importance  in 













availability  of  drugs  that  effectively  reduce Lp(a),  this  in 

















return  of  corpuscles  (plasmapheresis).  J  Pharmacol  Exp  Ther 
5:625–641
  2.  Al-Allaf FA, Coutelle C, Waddigton SN, David AL, Harbottle R 
(2010) LDLR-gene  therapy  for  familial  hypercholesterolaemia: 
problems,  progress,  and  perspectives.  International  Archives 
of  Medicine  3:36.  http://www.intarchmed.com/content/3/1/36. 
Accessed 2 Jan 2012













YL  (2011)  Low-density  lipoprotein  (LDL)  apheresis  reduces 
atherogenic and oxidative markers in uremic patients with hyper-
lipidemia. Int Urol Nephrol 43:471–474
















identification of  a defect  in  the  regulation of 3-hydroxy-3-met-





K,  Clark  BJ  III  ,  Stein  EA,  Lupien  PJ,  Brewer  HP  Jr,  Raper 
SE, Wilson  JM  (1995) A  pilot  study  of  ex  vivo  gene  therapy 
for  homozygous  familial  hypercholesterolemia.  Nat  Med 
1:1148–1154
14.  Julius U,  Siegert G, Gromeier  S  (2000)  Intraindividual  com-
parison  of  the  impact  of  two  selective  apheresis  methods 
(DALI and HELP) on the coagulation system. Int J Art Organs 
23:199–206
15.  Kamath BM, Oldhoff KM (2010) Liver  transplantation  in chil-
dren: update 2010. Pediatr Clin North Am 57:401–414
16.  Kastelein JJP, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, 
Chuang  E,  Graham MJ,  Crooke  RTL  (2006)  Potent  reduction 
of  apolipoprotein B  and  low-density  lipoprotein  cholesterol  by 
short-term administration of an antisense inhibitor of apolipopro-
tein B. Circulation 114:1729–1735




lesterol  lowering with  low-density  lipoprotein-apheresis: 1 year 
follow-up study. Clin Ther 16:416–428
18.  Knisel W, Di Nicuolo A, Pfohl M, Müller H, Risler T, Eggstein 
M, Seifried E  (1993) Different  effects  of  two methods of  low-
density lipoprotein apheresis on the coagulation and fibrinolytic 
systems. J Intern Med 234:479–487












22.  Maiorana A, Nobile V, Calandra  S,  Francalanci  P, Bernabei  S, 
El Hachem M, Monti L, Gennari F, Torre G, de Ville de Goyet 
J,  Bartuli A  (2011)  Preemptive  liver  transplantation  in  a  child 
















lowering  by  low-density  lipoprotein  apheresis  on  regression  of 
coronary  atherosclerosis  in  patients  with  familial  hypercholes-
terolemia:  Japan  low-density  lipoprotein  apheresis  coronary 
























lipoprotein  apheresis  in  familial  hypercholesterolemia. Circula-
tion 81:610–616


















U et  al  (1994) The HELP-LDL-apheresis multicentre  study,  an 




The  HELP-Study  Group.  Heparin-induced  extracorporeal  LDL 
precipitation. Eur J Clin Invest 24:724–732









41.  Stoffel W,  Greve V,  Borberg  H  (1981) Application  of  specific 
extracorporeal  removal  of  low-density  lipoprotein  in  familial 
hypercholesterolemia. Lancet II:1005–1007
42.  Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T 
(1997)  Single  LDL  apheresis  improves  endothelium-dependent 
vasodilatation  in  hypercholesterolemic  humans.  Circulation 
95:76–82
43.  Tatami R,  Inoue N,  Itoh H, Kishino B, Koga N, Nakashima Y, 
Nishide T, Okamura K, Saito Y, Teramoto T (1992) Regression 











koronarer  Herzkrankheit.  Kombination  einer  Plasmatherapie 
(HELP)  mit  HMG-CoA-Reduktasehemmern.  Therapiewoche 
38:3424–3437
46.  Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems 
with  the  use  of  viral  vectors  for  gene  therapy. Nat  Rev Genet 
4:346–358








Henderson  A  (1995)  Familial  hypercholesterolemia  regression 





51.  Von  Baeyer  H,  Schwerdtfeger  R,  Schwarzkopf W,  Schurig  R, 





apheresis  in  progression  of  coronary  artery  disease  in  patients 











B-containing  lipoproteins  for  plasmapheresis.  Arteriosclerosis 
4:276–282
56.  Zwiener RJ, Uauy R, Petruska ML, Huet BA (1995) Low-den-
sity  lipoprotein  apheresis  as  long-term  treatment  for  children 
with  homozygous  familial  hypercholesterolemia.  J  Pediatr 
126:728–735
